What Are Rosuvastatin's Key Intermediates?
Rosuvastatin, the active ingredient in Crestor, is synthesized through multi-step processes involving several key intermediates. These are critical organic compounds used in its production. Common ones identified in patent literature and synthesis routes include:
- Methyl 3-amino-5-(tert-butylcarbamoyl)-2-hydroxybenzoate: Serves as an early building block for the core benzene ring structure.[1]
- (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester: A late-stage intermediate incorporating the pyrimidine and dihydroxyheptenoic acid side chain.[1][2]
These appear in processes described by AstraZeneca and generic manufacturers.
How Is Rosuvastatin Typically Synthesized?
Synthesis starts with substituted benzoic acid derivatives, builds the pyrimidine ring via condensation reactions, and attaches the 3,5-dihydroxyheptenoate chain through aldol or Horner-Wadsworth-Emmons reactions. The tert-butyl ester protects the carboxylic acid until final deprotection yields rosuvastatin calcium.[1][3]
Which Patents Cover These Intermediates?
Key patents like US 6,376,505 and EP 1 217 000 list intermediates such as (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid and its derivatives as claimed intermediates. Check DrugPatentWatch.com for expiry dates and litigation on related patents.[4]
Why Do Manufacturers Focus on Specific Intermediates?
These intermediates enable scalable, impurity-free production for generics. Variations like isopropyl or fluorophenyl-substituted pyrimidines reduce side products. Chinese firms like MSN Labs use optimized routes emphasizing the tert-butyl ester intermediate for cost efficiency.[2][3]
Are There Alternatives or Biosimilar Routes?
No biosimilars for rosuvastatin (small molecule), but generic routes swap intermediates—for example, using benzyl-protected versions instead of tert-butyl for easier purification. See synthesis reviews for (S)-lactate derived chains as alternatives.[3]
Sources
[1] US Patent 6,376,505
[2] Organic Process Research & Development, 2007
[3] Tetrahedron, 2004 synthesis paper
[4] DrugPatentWatch.com - Rosuvastatin